-
Mashup Score: 2
Designed as a forum for leading US health system stakeholders, the ongoing addition of key health stakeholders and the inclusion of diverse sector perspectives facilitates the establishment of best practices and high standards that center on the needs of patients and the promotion of health equity.
Source: phrma.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1PBMs using 340B program to drive profits at patients’ expense - 29 day(s) ago
Congress should put an end to the exploitation of this important safety-net program and put it back on track for the patients it was meant to assist.
Source: phrma.orgCategories: General Medicine News, Hem/OncsTweet-
RT @oncologyCOA: PBMs using #340B program to drive profits at patients’ expense - from @phrma https://t.co/VFiGIAGK0b
-
-
Mashup Score: 7The drug development and approval process is about much more than the final “okay” - 4 month(s) ago
A recent Forbes story on the U.S. drug development process sends a misleading message to America’s patients and healthcare professionals.
Source: phrma.orgCategories: General Medicine News, Rare DiseaseTweet-
If nobody does often thankless pre-clinical work to identify things worth clincial trial investment & to weed out the duds, the clinical trial pipeline will dry up. You can't just do the clincal work w/o a ton of candidates being evaluated in pre-clinical. https://t.co/uYi5HGdvKY https://t.co/k4XNgAhHPX
-
-
Mashup Score: 4Congratulations to our 2023 Working for Cures Employee Champions - 5 month(s) ago
The annual Working for Cures Employee Champion Awards celebrate the people in our industry who go above and beyond to advance science and support the work our industry does for patients.
Source: phrma.orgCategories: General Medicine News, PayerTweet-
Our Vice President and Head of BioPharma Development Marci English was recently honored as a @PhRMA Working for Cures Employee Champion for improving awareness and care for the health challenges women at midlife experience during #menopause. Learn more: https://t.co/cPQ3p8m3Pe
-
-
Mashup Score: 5New Analysis Shows 340B Hospitals with Highest Operating Margins Provide Lowest Levels Charity Care - 6 month(s) ago
A new analysis from Health Capital Group examined the operating margins and charity care levels of 340B hospitals, finding financial wellness did not translate to 340B hospitals providing high levels of free or reduced cost care to vulnerable patients.
Source: phrma.orgCategories: General Medicine News, Hem/OncsTweet-
Color me shocked ! New Analysis Shows 340B Hospitals with Highest Operating Margins Provide Lowest Levels Charity Care https://t.co/E1mKm3M2p0
-
-
Mashup Score: 0Moonshot - 6 month(s) ago
America’s biopharmaceutical companies share President Biden’s commitment to eradicating cancer. With more than 1,300 medicines in the research pipeline, the science has never been more promising. But as industry research and development leaders warn in a letter to the Biden Administration, the Cancer Moonshot might have to call off its mission before it can get off the ground.
Source: phrma.orgCategories: General Medicine News, Future of MedicineTweet-
Open letter from biopharma leaders warns that policies like the IRA that may hinder innovation, limit R&D, affect accelerated approvals, and undermine IP protections. They urge pro-innovation policies and offer collaboration for shared goals https://t.co/Qw5qpxF3Fa
-
-
Mashup Score: 0New Analysis Shows Hospitals Mark Up Medicine Prices 500% - 9 month(s) ago
Hospitals are charging 500% of what they paid for medicines, on average, according to a new analysis from The Moran Company.
Source: phrma.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/RWfRf7Xbsn
-
-
Mashup Score: 1Inflation Reduction Act - 1 year(s) ago
Inflation Reduction Act’s Unintended ConsequencesSigned into law in 2022, the Inflation Reduction Act took important steps to lower out-of-pocket costs in Part D, including setting a $2,000 annual cap on what seniors pay for medicines and spreading seniors’ costs throughout the year to improve predictability. But it didn’t go far enough and has real consequences for the development of and access…
Source: phrma.orgCategories: Expert Picks, Latest HeadlinesTweet-
Due to Inflation Reduction Act 78% of drug companies expect to cancel early-stage pipeline projects that no longer make sense given the short timelines before medicines could be subject to government price setting. https://t.co/ijvXELyZWp
-
-
Mashup Score: 1Vas Narasimhan of Novartis Becomes Chair of PhRMA Board - 1 year(s) ago
The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Novartis CEO Vas Narasimhan, M.D., has assumed the role of chair of the PhRMA Board of Directors. Daniel O’Day of Gilead Sciences, Inc. and Albert Bourla of Pfizer Inc. also assumed new leadership positions on the PhRMA board.
Source: phrma.orgCategories: Latest Headlines, Rare DiseaseTweet-
RT @NedPagliarulo: $NVS Vas Narasimhan is PhRMA's new board chair, succeeding Takeda's Ramona Sequeira: https://t.co/R5I7vGFw1n Makes hi…
-
Launch Alert: U.S. Consensus Framework to Advance Health Equity & Ethical Collaborationđź”— Read more here: https://t.co/O3pIWEoFpZ and stay tuned for updates and learn how you can contribute to this vital cause. #HealthEquity #EthicalCollaboration #USHealthEcosystem https://t.co/4t9a2trWbM